Clinical trial

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

NCT02894398

Study summary

ClinicalTrials.gov

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Palbociclib Normalized identity: palbociclib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Letrozole Normalized identity: letrozole View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Anastrozole Normalized identity: anastrozole View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Exemestane Normalized identity: exemestane View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrant View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-09-06

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Hormone Receptor Positive Tumorunresolved

Human Epidermal Growth Factor 2 Negative Carcinoma of Breastunresolved

Interventions

PalbociclibDRUG · verified · RxNorm: palbociclib

LetrozoleDRUG · verified · RxNorm: letrozole

AnastrozoleDRUG · verified · RxNorm: anastrozole

ExemestaneDRUG · verified · RxNorm: exemestane

FulvestrantDRUG · verified · RxNorm: fulvestrant

Sponsors & collaborators

iOMEDICO AGlead sponsor

Pfizercollaborator

Mapped research locations

MünchenGermany2 GöttingenGermany2 BerlinGermany1 HamburgGermany1 DresdenGermany1 EssenGermany1 FrankfurtGermany1 MünsterGermany1 UlmGermany1 BonnGermany1 Freiburg im BreisgauGermany1 MannheimGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02894398 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.